Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
Elizabeth Trice LoggersRashmi ChughNoah FedermanLee HartnerRichard F RiedelSunny ChoDavid HyslopAllison LimAna B OtonKutluk H OktayPublished in: Cancer (2024)
Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient.